David Schlanger has been the driving force behind Progyny, Inc., a healthcare company, starting as CEO in January 2017 and transitioning to Executive Chairman in January 2022. Under his leadership, Progyny has taken significant steps in providing comprehensive fertility benefits,...

David Schlanger has been the driving force behind Progyny, Inc., a healthcare company, starting as CEO in January 2017 and transitioning to Executive Chairman in January 2022. Under his leadership, Progyny has taken significant steps in providing comprehensive fertility benefits, impacting many families. Schlanger previously led WebMD as CEO from 2013 to 2016, showcasing his strong background in digital health. He holds a degree from Georgetown University and a law degree from the University of Michigan. Importantly, his compensation reflects a shift in leadership; when he moved to the Executive Chairman role, his salary dropped to $250,000, but he could earn up to 100% of that amount in bonuses based on company performance. Schlanger's experience and hands-on approach have made him a key player in healthcare innovation, steering Progyny towards excellence in patient care and satisfaction.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Progyny CEOs

P

David Schlanger

Ex-CEO of Progyny

Education

Not specified

Field of Expertise

Healthcare & Life Sciences - Healthcare

Sector of Economy

Healthcare

Born

January 1, 1959 - 66 years ago

CEO of Progyny for

5 years 0 months (Jan 2017 - Jan 2022)

Previous Experience

CEO of WebMD

Rivals

Competitors/colleagues of David Schlanger

Holdings

See how much did David Schlanger make over time.

David Schlanger's holdings primarily consist of equity in Progyny, where he has vested significant stock options and restricted shares. In 2022 alone, he was granted 333,000 stock options and 84,000 restricted stock units. As of his transition to Executive Chairman,...

David Schlanger's holdings primarily consist of equity in Progyny, where he has vested significant stock options and restricted shares. In 2022 alone, he was granted 333,000 stock options and 84,000 restricted stock units. As of his transition to Executive Chairman, he had considerable wealth tied up in these shares, particularly when Progyny's stock performance surged. The decisions around his equity grants reflect Progyny’s performance goals. Despite his previous substantial compensation as CEO, which peaked around $862,462 in 2021, his stake in the company remains a driving factor for his financial success and aligns his interests with that of shareholders. Schlanger's wealth in his holdings significantly fluctuated during his tenure, highlighting the link between his leadership outcomes and stock market movements.

Total Stock Sold

$241.70M

PGNY

$241.70M

6,284,753 PGNY shares

What if they kept their stock?

If David Schlanger didn't sell their stock, today they would have:
Extra PGNY6,284,753 shares worth $119.85M.
This is -50.41% and $121.85M less than what they got when they sold the stock.

Charitable Transactions

PGNY

580,010 shares

PGNY

Recent Charitable Transactions

PGNY

580,010 shares

PGNY

Sep 15, 2020

Charity

Insider Trading

See recent insider trades of David Schlanger.

PGNY

$37.52K

PGNY at $37.52/share

Apr 1, 2024

Sale

PGNY

$2.69M

PGNY at $37.80/share

Mar 27, 2024

Sale

PGNY

$109.05K

PGNY at $37.58/share

Mar 25, 2024

Sale

PGNY

$219.88K

PGNY at $37.74/share

Mar 21, 2024

Sale

PGNY

$772.05K

PGNY at $38.60/share

Feb 5, 2024

Sale

PGNY

$2.32M

PGNY at $38.65/share

Feb 1, 2024

Sale

PGNY

$2.50M

PGNY at $37.88/share

Jan 8, 2024

Sale

PGNY

$526.02K

PGNY at $37.58/share

Jan 2, 2024

Sale

PGNY

$5.90M

PGNY at $37.80/share

Dec 26, 2023

Sale

PGNY

$6.15M

PGNY at $37.75/share

Dec 20, 2023

Sale

Compensation History

See how much did David Schlanger make over time.

In 2022, David Schlanger's total compensation was $2,611,600, down from over $800,000 in previous years when he was CEO. This included a much lower base salary of $250,000 after transitioning to Executive Chairman. His package consisted of a performance bonus opportunity that could double his base salary. Much of his previous compensation included substantial performance-based bonuses and stock options, with 84,000 restricted stock units vesting over three years. This structure incentivized him to continue driving Progyny forward, aligning his financial rewards with the company's success and ensuring he remains focused on improving outcomes for patients.

Year

2022

Total Compensation

$3.13M

Salary

$250.00K

Board Justification

The compensation program is designed to attract and retain highly qualified executives, motivate them to achieve company goals, and align their interests with those of stockholders through equity awards.

Bonus

$250.00K

Board Justification

Eligible for an annual discretionary performance and retention bonus of up to a maximum of 100% of his annual salary, based on performance metrics.

Other

$10.41K

Board Justification

Includes matching contributions to the 401(k) plan and payment of term life insurance premiums.

Restricted Stock

$2.62M(84 RSU)

Board Justification

84,000 RSUs granted on January 1, 2022, vesting 25% on the first anniversary and the remaining 75% in equal quarterly installments over the next three years, subject to continued service.

Performance Metrics

Performance metrics include sales growth, clinical outcomes, member services, provider network quality, organizational culture, and strategic initiatives.

Other Progyny CEOs

Here are other CEOs of Progyny

Pete Anevski

CEO of Progyny

January 2022 - Present